PHP32 THE STATE OF HEALTH STATUS MEASUREMENT IN LATIN AMERICA  by Zarate, V & Kind, P
A31Abstracts
professionals and public. CONCLUSION: In last 15 years the
EU15 countries realized the reforms concerning ﬁnancing of
health care. Main goal was to slow down an increased tempo in
health care expenditures ﬁnanced from public sources, with
focus on drug reimbursement. Improvement of health care ser-
vices, solidarity, equity, access of quality care for all, including
lower income groups, are important tasks of reforms. Czech
Republic, with its average expenses on drugs from GDP (2%)
and its average expenses on health care (29% in 2004), belongs
to countries with the highest drug consumption. Increase in drug
expenses over last 5 years is mainly due to increase of average
price for individual package, not by increasing of number of
packages on patient, and increased number of prescriptions on
inhabitant.
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OBJECTIVES: This project was conducted as part of a federally
funded national pilot to evaluate electronic prescribing in the
community practice setting. The objective of this analysis was to
measure the attitudes of chain community pharmacists and tech-
nicians toward e-prescribing and the processing of e-prescrip-
tions. METHODS: A self-administered survey was distributed to
pharmacists and technicians practicing in 422 stores operated by
seven chain pharmacy organizations in six states. RESULTS: A
total of 1094 surveys were returned from pharmacy personnel
practicing in 276 stores. Pharmacy personnel rated e-prescrip-
tions as preferred to conventional prescriptions on each of seven
desired outcomes of care. Pharmacists were found to view e-
prescribing more positively than technicians (p < 0.05) for its 
net effect on three key outcomes: patient safety, effectiveness of
care and efﬁciency of care. No differences were found between
personnel classes in their overall satisfaction with e-prescribing
as all were found to be moderately satisﬁed when comparing this
technology to conventional prescribing and prescription pro-
cessing. A total of 2235 written comments were received on the
returned surveys. Of these, 57% (1277) mentioned negative fea-
tures of e-prescribing, while 43% (958) were positive features.
Among the positive features mentioned, improved clarity and/or
legibility of prescriptions was the most frequently cited advan-
tage of e-prescribing, followed closely by improved speed or 
efﬁciency of processing. Prescribing errors, particularly those
containing a wrong drug or wrong directions were the most com-
monly cited negative feature of e-prescribing (34.1%). CON-
CLUSION: Chain pharmacy personnel are generally satisﬁed
with the current status of e-prescribing, but also perceive key
weaknesses in how it has been implemented in physicians’ prac-
tices and their own organizations. From analysis of the data and
follow-up interviews, twelve (12) best practice recommendations
are offered to improve e-prescribing in the community setting.
PHP31
EXAMINATION OF THE VALUE OF LAB DATA IN HEALTH
CARE MANAGEMENT
Ye X, Gams E,Anetsberger H,Asch K, Sun SX, Lee KY, Bertram CT
Walgreens Health Services, Deerﬁeld, IL, USA
OBJECTIVES: The purpose of the study was to examine the
value of the lab data in light of a participant’s self-reported, phar-
macy claims, and medical claims information by comparing the
distribution of the some common chronic conditions. A second
purpose was to identify participants with different Body Mass
Index (BMI) who were at risk for certain conditions and examine
their usage of medications. METHODS: Descriptive frequency
distributions were conducted to address the research questions.
The data for this study came from four sources of a large
national pharmacy beneﬁt manager’s client: Health Risk Assess-
ment (HRA) questionnaire which consists of about 50 survey
questions, pharmacy claims, medical claims and lab data. The
total sample size was 341. We compared the distributions of four
disease conditions in self-reported, pharmacy claims, medical
claims, and lab tests. Secondly, we examined the number of par-
ticipants in three body mass index BMI categories who are at
risk for three conditions, yet who have not been taking any med-
ications for these conditions. RESULTS: The results show that
combined with the survey, pharmacy and medical data, the lab
data helped to identify 84 participants at risk for diabetes, 95
participants at risk for dyslipidemia, 24 participants at risk for
hypertension, and 8 participants at risk for kidney disease. These
participants had abnormal lab values, but did not have a self
report, pharmacy claims, or medical claims for the conditions.
The results also show that the percentage of participants at risk
for hypertension, dyslipidemia, and diabetes increased as their
BMI goes up. In addition, a signiﬁcant number of participants
with abnormal lab values have not been on medications. CON-
CLUSION: The lab data helps identify a group of at-risk par-
ticipants who may need to be targeted for some kind of medical
intervention. This has a potential cost-saving effect.
PHP32
THE STATE OF HEALTH STATUS MEASUREMENT IN 
LATIN AMERICA
Zarate V1, Kind P2
1Pontiﬁcia Universidad Catolica de Chile, Santiago, Chile, 2Outcomes
Research Group, Centre for Health Economics, University of York,
York, UK
OBJECTIVES: Regulatory agencies and other national bodies in
countries across the world now demand health-related quality of
life (HRQOL) data—for multiple applications that range from
technology appraisal to monitoring health inequalities and the
measurement of population health. Little is known about the
state of HRQOL research in Latin America over the last 20
years. METHODS: Systematic electronic searches of SCIELO,
LILACS and MEDLINE were conducted to identify published
studies that used SF-36, SF-12, SF-8, HUI or EQ-5D as a generic
HRQOL instrument in 27 Latin American countries from 1987
onward. RESULTS: Prior to the 1990s there was virtually no evi-
dence of the use of HRQOL instruments in the majority of 
the Latin American countries. Electronic searches retrieved 115
records from 12 different countries; only 6 records were multi-
national studies. The vast majority of published material has
only emerged within the past 6 years. 105 records were published
from 2000 onwards. Brazil was the highest producer of single-
country HRQOL studies (n = 81 records). The SF-36 survey 
was the most frequently used instrument to measure generic
HRQOL, followed by the HUI, the SF-12 and the EQ-5D VAS.
The main use of generic HRQOL instruments has been in the
evaluation of quality of life for particular health conditions and
the validation of other, condition-speciﬁc instruments. CON-
CLUSION: Health status measurement is a ﬁeld of growing
interest in Latin America although much remains to be done in
order to ease the process of incorporating the measurement of
HRQOL to traditional health indicators of morbidity and mor-
tality. The main barriers to overcome in the future for Latin
American countries are ﬁrstly the lack of qualiﬁed or skilled
outcome researchers and secondly the limited number of valida-
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tion studies related to generic HRQOL instruments. To achieve
parity with developments elsewhere regionally-relevant research
in this ﬁeld is a priority.
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PRELIMINARY EFFECTS OF A NEW NURSE-PHARMACIST
CLINICAL PREVENTION PROGRAM ON MEDICATION USE
Krueger KP1, Hunter ML1, Campbell S1,2, Fiske M2, Macnee C1
1University of Wyoming, Laramie, WY, USA, 2HCMSGroup, Cheyenne,
WY, USA
The Healthy Families Succeed Pilot used nurse-pharmacists
teams to test the effects of a home visitation, family-centered,
clinical prevention intervention on health, service utilization and
self-sufﬁciency. OBJECTIVES: 1) Describe the types of medica-
tion-related interventions of the teams; 2) determine factors asso-
ciated with polypharmacy; and 3) determine the impact the
teams had on adherence. METHODS: Design: randomized, two
group comparison. Selection: Inclusion criteria: use of multiple
state programs and polypharmacy (≥10 unique drugs/year).
Exclusion: age ≥ 65, incarceration. Process: Two nurse-pharma-
cist teams participated. Nurses made home visits throughout the
pilot study. Pharmacists reviewed records, made home visits and
served as consultants to the nurses and families. Analysis: Inter-
views with the teams were used to collect data related to the
interventions and families’ patterns of medication use. Regres-
sion analysis was performed on integrated health and social
claims data to identify factors related to polypharmacy and
adherence to medication regimens (measured by medication pos-
session ratios). RESULTS: Thirty-ﬁve families were assigned to
the study group and 33 in the control group. The teams found
medication problems in 97% of the intervention households.
Problems included: adherence (44%); lack of disease control
(37%); administration/storage problems (30%); ADR/interac-
tions (25%); and no indication for medication use (28%).
Factors associated with poly-pharmacy included: increasing age,
female gender, number of providers, number of ER visits, pres-
ence of a mental health or respiratory diagnosis, number of 
diagnoses, and county of residence. Medication ﬁlls/month and
average MPR increased, while the number of unique drugs
declined in the study group, relative to the control group. CON-
CLUSIONS: Most medication problems were related to lack of
understanding. Poor adherence was commonly associated with
lack of timely access to understandable information. Families
used the education and support provided by the teams to
improve adherence. Polypharmacy is an effective measure for
identifying families in need of clinical prevention.
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OBJECTIVES: The objectives of this study were to: 1) examine
the exposure rates to clinically important drug-drug interactions
(DDIs) within ambulatory care setting of the Veterans Affairs
Medical Centers (VAMCs), and 2) examine the association
between the structure of pharmaceutical services within the
ambulatory care setting of the VAMCs and DDI exposure rates.
METHODS: The study employed an observational, descriptive,
cross-sectional design, consisting of a retrospective database
analysis of pharmacy records to identify the exposure rate of
potential DDIs, and a mailed questionnaire to pharmacy direc-
tors to collect information about the characteristics of pharma-
ceutical services within the ambulatory care setting of VAMCs.
The time frame employed to identify DDI exposures was
between July 1, 2003 and June 30, 2004. A multivariate regres-
sion model was used to assess the association between domains
of pharmaceutical services and exposure rates to potential DDIs.
RESULTS: Pharmacy records from 2,795,345 veterans who ﬁlled
prescriptions at 128 VAMCs were analyzed. Overall, the rate 
of exposure to potential DDIs was 21.54 per 1,000 veterans
exposed, ranging from 9.65 to 32.32. Of the 563 ambulatory
clinics, 272 (48.3%) had pharmacist coverage. Anticoagulation
clinics were the most commonly reported ambulatory clinics, and
clinical pharmacy services were most commonly reported in ther-
apeutic drug monitoring clinics. After controlling for the total
number of pharmacists on staff, lower rates of potential DDIs
were observed in VAMCs with a higher number of specialty
ambulatory clinics and lower prescription volumes (p < 0.05).
CONCLUSION: The study observed wide variation in the rate
of exposure to clinically important DDIs within VAMC ambu-
latory care settings. Lower rates of exposure to potential DDIs
were noted in VAMCs with a higher number of specialty ambu-
latory clinics and lower prescription volumes.
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OBJECTIVES: The effectiveness of Medication Therapy Man-
agement Programs (MTMP), as deﬁned in the Medicare Mod-
ernization Act, at reducing adverse drug events (ADEs) may vary
depending on the MTMP structure and delivery method. The
cost-effectiveness of such programs are not known. To estimate
the break-even and cost-effectiveness thresholds for MTMP spe-
cialized in ADE prevention in ambulatory patients from a third
party payer perspective. METHODS: A Markov model was
developed using a hypothetical cohort of 1,000 patients. A sys-
tematic review was conducted to estimate probabilities and costs
for preventable and non-preventable ADEs, and the associated
permanent disability and mortality. Breakeven and cost-
effectiveness analyses were conducted by altering the effective-
ness of the MTM program at reducing preventable ADEs and
calculating 10-year costs, life expectancy, and breakeven points.
RESULTS: Probabilities and costs were primarily obtained from
a cohort study of all Medicare enrollees (30397 person-years of
observation) cared by a multispeciality group practice during a
12-month study period. As the relative risk reduction of the
MTM program on preventable ADEs was varied from 0.1 to 1,
the 10-year cost offset (breakeven cost) of the MTM program
varied from $75,500 to $272,900 per 1000 persons, life years
gained varied from 0.9 to 8.2 per 1000 persons, healthy life years
gained varied from 1.3 to 11.6 per 1000 persons. Assuming a
cost-effectiveness threshold of $100,000, the 10-year costs of the
MTM program could approach $160,500 (RRR = 0.1) to
$1,432,900 (RRR = 1) per 1000 persons to be considered cost-
effective. CONCLUSION: The breakeven points for MTM 
programs specialized in ADE prevention were realistic and
attainable. Generally speaking, MTM programs should be
viewed as cost-effective. The cost-effectiveness of individual pro-
grams will depend heavily on the effectiveness of such programs
in reducing preventable ADE’s, as demonstrated by the wide
range in breakeven points.
